Leiden University Medical Center, Leiden, Netherlands
Nienke A De Glas , Esther Bastiaannet , Frederiek van den Bos , Simon Mooijaart , Astrid Aplonia Maria Van Der Veldt , Karijn Suijkerbuijk , Maureen J.B. Aarts , Franchette van den Berkmortel , Christian U. Blank , Marye Boers-Sonderen , Alfonsus Johannes Maria van den Eertwegh , Jan Willem de Groot , Geke Hospers , John B. A. G. Haanen , Djura Piersma , Rozemarijn Van Rijn , A. J. Ten Tije , Michel W.J.M. Wouters , Johanna Elisabeth A. Portielje , Ellen Kapiteijn
Background: Checkpoint inhibitors have strongly improved survival of patients with metastatic melanoma. Trials suggest no differences in outcomes between older and younger patients, but only relatively young patients with a good performance status were included in these trials. The aim of this study was to describe treatment patterns and outcomes of older adults with metastatic melanoma, and to identify predictors of outcome. Methods: We included all patients aged ≥65 years with metastatic melanoma between 2013 and 2020 from the Dutch Melanoma Treatment registry (DMTR), in which detailed information on patients, treatments and outcomes is available. We assessed predictors of grade ≥3 toxicity and 6-months response using logistic regression models, and melanoma-specific and overall survival using Cox regression models. Additionally, we described reasons for hospital admissions and treatment discontinuation. Results: A total of 2216 patients were included. Grade ≥3 toxicity did not increase with age, comorbidity or WHO performance status, in patients treated with monotherapy (anti-PD1 or ipilimumab) or combination treatment. However, patients aged ≥75 were admitted more frequently and discontinued treatment due to toxicity more often. Six months-response rates were similar to previous randomized trials (40.3% and 43.6% in patients aged 65-75 and ≥75 respectively for anti-PD1 treatment) and were not affected by age or comorbidity. Melanoma-specific survival was not affected by age or comorbidity, but age, comorbidity and WHO performance status were associated with overall survival in multivariate analyses. Conclusions: Toxicity, response and melanoma-specific survival were not associated with age or comorbidity status. Treatment with immunotherapy should therefore not be omitted solely based on age or comorbidity. However, the impact of grade I-II toxicity in older patients deserves further study as older patients discontinue treatment more frequently and receive less treatment cycles.
anti-PD(L)1 | Ipilimumab | Ipilimumab + nivolumab | p-value | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
% of treated patients with toxicity | OR | 95% C.I. | p-value | % of treated patients with toxicity | OR | 95% C.I. | p-value | % of treated patients with toxicity | OR | 95% C.I. | ||
Age | ||||||||||||
65-74 75+ | 13.9 16.6 | Ref 1.23 | (0.86-1.77) | 0.255 | 31.9 31.0 | Ref 0.96 | (0.60-1.52) | 0.859 | 41.0 47.4 | Ref 1.02 | (0.96-1.09) | 0.543 |
Number of comorbidities | ||||||||||||
0 1-2 3 or more Unknown | 12.1 15.3 16.0 15.8 | Ref 1.32 1.39 1.37 | (0.71-2.45) (0.75-2.60) (0.35-5.29) | 0.781 | 28.6 32.7 32.8 0.0 | Ref 1.22 1.22 . | (0.67-2.20) (0.65-2.28) | 0.922 | 43.9 46.7 34.4 55. | Ref 1.12 0.67 1.60 | (0.53-2.35) (0.30-1.51) (0.37-6.83) | 0.410 |
WHO classification | ||||||||||||
0 1 2 3 or 4 Unknown | 15.2 15.1 22.4 0.0 11.8 | Ref 0.99 1.61 . 0.75 | (0.66-1.48) (0.89-2.93) (0.34-1.63) | 0.480 | 34.3 25.9 50.0 0.0 27.8 | Ref 0.67 1.91 . 0.74 | (0.40-1.12) (0.65-5.68) (0.34-1.61) | 0.321 | 47.8 40.5 45.0 . 28.6 | Ref 0.75 0.89 . 0.44 | (0.40-1.40) (0.34-2.37) (0.13-1.50) | 0.704 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Christoffer Gebhardt
2023 ASCO Quality Care Symposium
First Author: Ayo Samuel Falade
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
First Author: Harsh V Parmar
2021 ASCO Annual Meeting
First Author: Shivanshan Pathmanathan